Enterprise Value
2.925B
Cash
822.2M
Avg Qtr Burn
-123.1M
Short % of Float
7.99%
Insider Ownership
0.74%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AYVAKIT (avapritinib) Details PDGFRA mutant GIST (Gastrointestinal Stromal Tumors) | Approved Quarterly sales | |
(AYVAKIT®) (avapritinib) Details Systemic Mastocytosis | Approved Quarterly sales | |
GAVRETO (parlsetinib) Details RET+ NSCLC (Non-small cell lung cancer), RET+ Thyroid cancer, solid tumors | Approved Quarterly sales | |
AYVAKIT (avapritinib) Details Systemic Mastocytosis | Approved Quarterly sales | |
BLU-451 Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1/2 Update | |
BLU-945 +/- osimertinib Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1/2 Update | |
BLU-222 (CDK12) Details Cancer, Breast cancer | Phase 1/2 Update |